Horizon Therapeutics plc: Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
Meeting plenary session to feature 12-Month data from MIRROR randomized controlled trial of KRYSTEXXA (pegloticase) injection with methotrexate - Horizon Therapeutics plc (Nasdaq: HZNP) today announced
Source: finanznachrichten.de